GRAL
Grail Inc
How Do They Make Money?
How Do They Make Money?GRAIL (a Illumina spinoff) sells multi-cancer early detection (MCED) blood tests (Galleri) and monetizes its methylation tech via development services. In 2024 it did ~$125.6M revenue (+35% YoY) but remains loss-making while scaling and pursuing FDA approval and reimbursement. It uses algorithms, machine learning and other techniques to improve accuracy of this tests.
Revenue Streams:
Galleri screening (≈86.5% of revenue in 2024 |~$108.6M):
A lab-developed blood test that can detect signals associated with 50+ cancers and indicate likely tissue of origin.Development Services (≈13.5% ~$17.0M):
Contract work for biopharma and health systems: clinical-study support, biomarker discovery/companion Dx, pilot research, and precision-oncology assays (e.g., minimal-residual-disease and monitoring).
Pricing & Volume:
List price: $949 per test (U.S.).
Realized price: ~$790 on average after discounts for large buyers.
Volumes: >137k Galleri tests sold in 2024 (vs. ~100k in 2023).
Customers & Go-to-Market:
Prescribing clinicians: >2,400 physicians ordering Galleri.
Health systems: Integrated delivery networks and major cancer centers.
Employers: Self-insured companies offering Galleri as a benefit.
Insurers & life insurers: Select coverage pilots and wellness integrations.
Distribution boost: Quest Diagnostics channel access for national reach.
Tech & Moat:
Core platform: Cell-free DNA methylation profiling + machine-learning classifiers.
Claims: High specificity (~99.5%), tissue-of-origin prediction (~88% accuracy), detection across >50 cancers (many without existing screening).
Moat drivers: Large clinical datasets (hundreds of thousands of participants), operating lab infrastructure, payer/provider relationships, and an extensive IP estate (>1,000 patents).
Competition:
Principal rivals building MCED
or adjacent assays include Guardant Health, Freenome, Exact Sciences/Thrive, and Natera. Differentiation hinges on validation scale, performance, cost per test, and reimbursement progress.
Market Opportunity:
Near-term TAM (MCED): ~$1–1.3B in 2024, projected ~$2.9–4.3B by 2030 (CAGR ~17–27%).
Eligible populations: Tens of millions of higher-risk adults across the U.S., UK, EU, and Japan.
Growth Levers:
Regulatory: Modular PMA submission targeted for 1H 2026; a green light would unlock broader Medicare/private payer coverage.
Payer adoption: Momentum with select plans (e.g., TRICARE) and large employer benefits.
International: Ongoing UK NHS Galleri study (>140k participants) with readout expected 2026; potential national rollout.
Productivity: 2024 automation upgrade to expand capacity and reduce sequencing costs.
Summary:
GRAIL currently makes money by selling Galleri tests and licensing its science via development services. The path to meaningful profitability runs through FDA approval, broad payer coverage, falling unit costs, and continued clinical validation. High risk, potentially transformative upside if MCED becomes a standard layer of population screening. Explanation what MCEDs are: https://www.cancer.org/cancer/screening/multi-cancer-early-detection-tests.html
https://grail.com/press-releases/grail-reports-fourth-quarter-and-full-year-2024-financial-results
https://grail.com/press-releases/grail-reports-second-quarter-2025-financial-results
https://www.sec.gov/Archives/edgar/data/1699031/000169903125000041/gral-20241231.htm
https://www.fiercebiotech.com/medtech/grail-launches-its-50-cancer-galleri-blood-screening-test